XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Prostate Channel
subscribe to Prostate newsletter

Latest Research : Cancer : Prostate

   DISCUSS   |   EMAIL   |   PRINT
Toremifene May Reduce Cancer Risk in Men with Precancerous Prostate Cells
May 17, 2005, 01:54, Reviewed by: Dr.

"This is the first time that a drug has shown promise for lowering the incidence of prostate cancer in men with PIN"

 
In a multicenter phase IIb study, the hormone drug toremifene (Acopodene) reduced the risk of prostate cancer development by nearly half in men with prostatic intraepithelial neoplasia (PIN), a precancerous condition that can progress to prostate cancer.

"This is the first time that a drug has shown promise for lowering the incidence of prostate cancer in men with PIN," said lead author David Price, MD, Director of Urologic Oncology and Clinical Research at Regional Urology, LLC in Shreveport, Louisiana. Toremifene, a hormonal therapy commonly used to treat women with advanced breast cancer, may work by blocking a particular estrogen receptor that has been implicated in prostate cancer development.
While PIN does not always lead to prostate cancer, prostate cancer usually develops in men with PIN. Approximately 10% of men who undergo prostate biopsies are diagnosed with PIN, and more than 30% of men with PIN will be diagnosed with prostate cancer within a year.

Currently, there is no effective treatment for PIN � men with this condition receive periodic biopsies, and many live with a fear of developing cancer. Prostate cancer is the most common cancer in men in the United States � more than 200,000 cases are expected to be diagnosed in 2005.

In this study, 514 men with PIN were randomly assigned to receive 20 mg, 40 mg, or 60 mg of toremifene or a placebo for one year, undergoing prostate biopsies at six and 12 months. The trial was completed in May 2004.

The cumulative incidence of prostate cancer was 31.2% in the placebo group at one year. Patients treated with 20 mg of toremifene for six months had a 22% reduction in prostate cancer, while patients who completed an entire year of treatment had a 48% reduction in prostate cancer risk (24.4% cumulative incidence). For the groups that received 40 mg and 60 mg of toremifene, the 12-month incidence of prostate cancer was also lower, but not statistically significant (18% and 25.3% risk reductions, respectively).

Toremifene was generally well tolerated, with the incidence of adverse events occurring at a similar rate in the toremifene-treated groups as the placebo group; the exception was fatigue, which occurred in 5% of patients treated with toremifene versus 3% of the placebo group.

"While these data are promising, more clinical trials are needed to determine whether toremifene should be widely prescribed to men with prostatic intraepithelial neoplasia," Dr. Price added.
 

- American Society of Clinical Oncology Annual Meeting
 

www.asco.org

 
Subscribe to Prostate Newsletter
E-mail Address:

 

Lead Author:
David Price, MD
Regional Urology, LLC
Shreveport, LA


Related Prostate News

Gene therapy study takes aim at prostate cancer
Pain associated with prostatic biopsy is related to the site biopsied
Admixture mapping reveals locus for prostate cancer risk
Diet modification and stress reduction may attenuate progression of prostate cancer
Prostatic Irradiation Doesn�t Lead To Any Appreciable Increase in Rectal Cancer Risk
Pomegranate Juice Slows PSA Acceleration Rate
Pomegranate juice could kill cancer cells
Early estrogen exposure leads to later prostate cancer risk
JHDM2A enzyme induced H3K9 demethylation offers new look at male hormone regulation
What is the appropriate age to stop prostate cancer screening?


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us